The Recreational use of phosphodiesterase 5 inhibitors among young healthy university male students in Tanzania: A cross-sectional study
DOI:
https://doi.org/10.66354/gshs8p46Keywords:
Phosphodiesterase 5 inhibitors (PDE5i) , Erectile dysfunction (ED), Recreational use, University studentsAbstract
Background: Phosphodiesterase-5 inhibitors (PDE5i) are approved for erectile dysfunction but increasingly misused by young men without medical indications. Such non-medical use raises concerns about adverse effects, drug interactions, and risky sexual behaviours.
Objectives: To determine the prevalence and factors associated with recreational use of PDE5i among healthy male university students in Tanzania.
Methods: This was a cross-sectional study conducted at the Catholic University of Health and Allied Sciences (CUHAS) between April and July 2020, involving male undergraduate students enrolled in medicine, pharmacy, nursing, laboratory sciences, and diploma programmes.
A semi-structured online questionnaire was administered via a secure Google Forms platform, with an embedded electronic informed consent form completed before enrolment. Data collected included participant demographics, medical history, substance use, and PDE5i-related knowledge and practices. Logistic regression was used to determine independent factors of PDE5i use.
Results: A total of 196 male undergraduate students were enrolled, with a mean age of 24±2.2 years, and 7.7% (15/196) reported PDE5i use. Most accessed drugs without prescription (60%), mainly sildenafil (73.3%). Common side effects included headache (53.3%) and dizziness (46.7%). Older age, cigarette smoking, alcohol consumption, and having a sexual partner were associated with use in crude analysis, but only older age (AOR 4.04, 95% CI 1.20–13.61) and cigarette smoking (AOR 6.8, 95% CI 1.17–39.4) remained independent predictors.
Conclusions: Non-medical PDE5i use for sexual enhancement was present among university students, associated with older age and cigarette smoking. These findings highlight the need for awareness of the risks of misuse and stricter regulation of non-prescription access.
References
Korkes F, Costa-Matos A, Gasperini R, Reginato PV, Perez MDC. Recreational use of PDE5 inhibitors by young healthy men: recognizing this issue among medical students. J Sex Med. 2008;5(10):2414–8.
Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol. 1996;78(2):257–61.
Bechara A, Casabé A, De Bonis W, Helien A, Bertolino MV. Recreational use of phosphodiesterase type 5 inhibitors by healthy young men. J Sex Med. 2010;7(11):3736–42.
Aldridge J, Measham F. Sildenafil (Viagra) is used as a recreational drug in England. BMJ. 1999;318:669.
Lee JH, Park OR, Yang YJ, Han JH, Jung EJ, Kim NS, et al. Detection of 94 PDE-5is and their analogs including N-desmethylthiosildenafil in various formulations of dietary supplements and food samples using HPLC and LC-Q-TOF/MS. J Chromatogr Sci. 2022;60(10):953–62.
Attia AAA, Abdel-Hameed AKS, Amer MAEM, Mamdouh H, Gamal El Din SF, El-Moslemany HEDGM. Study of the prevalence and patterns of phosphodiesterase type 5 inhibitor use among sexually active Egyptian males: a national cross-sectional survey. Andrologia. 2019;51(9):e13352.
Bekele R. A matter of sexual confidence: young men’s non-prescription use of Viagra in Addis Ababa, Ethiopia. Cult Health Sex. 2016;18(5):495–508.
Erku DA, Mekuria AB, Surur AS, Gebresillassie BM. Extent of dispensing prescription-only medications without a prescription in community drug retail outlets in Addis Ababa, Ethiopia: a simulated-patient study. Drug Healthc Patient Saf. 2016;8:65–70.
Swearingen SG, Klausner JD. Sildenafil use, sexual risk behavior, and risk for sexually transmitted diseases, including HIV infection. Am J Med. 2005;118(6):571–7.
Gebreyohannes EA, Bhagavathula AS, Gebresillassie BM, Tefera YG, Belachew SA, Erku DA. Recreational use of phosphodiesterase 5 inhibitors and its associated factors among undergraduate male students in an Ethiopian university: a cross-sectional study. World J Mens Health. 2016;34(3):186–92.
Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. PT. 2013;38(7):407–19.
Khalaf I, Levinson I. Erectile dysfunction in the Africa/Middle East region: epidemiology and experience with sildenafil citrate (Viagra). Int J Impot Res. 2003;15(Suppl 1):S1–2.
Kagashe GA, Minzi OM, Matowe LK. An assessment of dispensing practices in private pharmacies in Dar-es-Salaam, Tanzania. Int J Pharm Pract. 2011;19(1):30–5.
Smith KM, Romanelli F. Recreational use and misuse of phosphodiesterase 5 inhibitors. J Am Pharm Assoc. 2005;45(1):63–76.
Tanzania Commission for AIDS (TACAIDS). Tanzania HIV Impact Survey (THIS): a population-based HIV impact assessment. 2019. p. 1–6